Literature DB >> 22287594

Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.

Silvia Tremosini1, Alejandro Forner, Loreto Boix, Ramon Vilana, Luis Bianchi, Maria Reig, Jordi Rimola, Carlos Rodríguez-Lope, Carmen Ayuso, Manel Solé, Jordi Bruix.   

Abstract

BACKGROUND AND AIMS: Conventional pathological analysis fails to achieve sufficient sensitivity and specificity for the diagnosis of hepatocellular carcinoma (HCC) in small nodules. Immunohistochemical staining for glypican 3 (GPC3), heat shock protein 70 (HSP70) and glutamine synthetase (GS) has been suggested to allow a confident diagnosis but no prospective study has established the diagnostic accuracy of this approach. The aim of this study is to assess prospectively the diagnostic accuracy of a panel of markers (GPC3, HSP70, GS) for the diagnosis of HCC in patients with cirrhosis with a small (5-20 mm) nodule detected by ultrasound screening.
METHODS: Sixty patients with cirrhosis with a single nodule 5-20 mm newly detected by ultrasound were included in the study. Contrast-enhanced ultrasound, magnetic resonance and fine needle biopsy of the nodule (gold standard) were performed; the biopsy was repeated in case of diagnostic failures. Three consecutive sections of the first biopsy sample with meaningful material were stained with antibodies against GPC3, HSP70 and GS.
RESULTS: Forty patients were diagnosed with HCC. The sensitivity and specificity for HCC diagnosis were: GPC3 57.5% and 95%, HSP70 57.5% and 85%, GS 50% and 90%, respectively. The sensitivity and specificity of the different combinations were: GPC3+HSP70 40% and 100%; GPC3+GS 35% and 100%; HSP70+GS 35% and 100%; GPC3+HSP70+GS 25% and 100%. When at least two of the markers were positive (regardless of which), the sensitivity and specificity were 60% and 100%, respectively. Conventional pathological analysis yielded three false negative results, but the addition of this panel only correctly classified one of these cases as HCC.
CONCLUSION: These data within a prospective study establish the clinical usefulness of this panel of markers for the diagnosis of early HCC. However, the panel only slightly increases the diagnostic accuracy in an expert setting.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22287594     DOI: 10.1136/gutjnl-2011-301862

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  44 in total

1.  Molecular Profiling and Research of Therapeutic Targets.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  Dig Dis       Date:  2015-07-06       Impact factor: 2.404

2.  Pathway of care of hepatocellular carcinoma in 2017.

Authors:  Federica Invernizzi; Massimo Colombo
Journal:  Hepat Oncol       Date:  2017-06-21

3.  Sex-determination gene SRY potentially associates with poor prognosis but not sex bias in hepatocellular carcinoma.

Authors:  Tong-Chun Xue; Lan Zhang; Zheng-Gang Ren; Rong-Xin Chen; Jie-Feng Cui; Ning-Ling Ge; Sheng-Long Ye
Journal:  Dig Dis Sci       Date:  2014-10-02       Impact factor: 3.199

4.  Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients.

Authors:  B Li; H Liu; H W Shang; P Li; N Li; H G Ding
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

Review 5.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

6.  Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.

Authors:  Jordi Rimola; Alejandro Forner; Víctor Sapena; Neus Llarch; Anna Darnell; Alba Díaz; Angeles García-Criado; Lluís Bianchi; Ramon Vilana; Álvaro Díaz-González; Carmen Ayuso; Jordi Bruix; María Reig
Journal:  Eur Radiol       Date:  2019-08-01       Impact factor: 5.315

7.  Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10.

Authors:  Tobias Eggert; Katherine A McGlynn; Austin Duffy; Michael Peter Manns; Tim F Greten; Sean F Altekruse
Journal:  Gut       Date:  2013-05-25       Impact factor: 23.059

8.  Glutamine synthetase predicts adjuvant TACE response in hepatocellular carcinoma.

Authors:  Bo Zhang; Kai Liu; Jian Zhang; Liwei Dong; Zhichao Jin; Xinji Zhang; Feng Xue; Jia He
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 9.  Glypican-3 antibodies: a new therapeutic target for liver cancer.

Authors:  Mingqian Feng; Mitchell Ho
Journal:  FEBS Lett       Date:  2013-10-15       Impact factor: 4.124

10.  Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma.

Authors:  Thuy B Nguyen; Massimo Roncalli; Luca Di Tommaso; Sanjay Kakar
Journal:  Mod Pathol       Date:  2016-01-15       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.